A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus

NCT02501161 on ClinicalTrials.gov · last registry update 2019-11-27

An unusually large phase 3: 1,012 participants, more than double the 424 typical for the stage. The sponsor logged completion for 3 October 2018. Primary outcome, as filed: Time From Randomisation to Inadequate Glycaemic Control and Need for Treatment Intensification. liraglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 1,012
Started: 2016-01-31
Primary completion: 2018-10-03 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Time From Randomisation to Inadequate Glycaemic Control and Need for Treatment Intensification

Conditions studied

Diabetes · Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.